insulin lispro


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to insulin lispro: Insulin glargine

insulin lispro

(lĭs′prō′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by a reversal in the order of lysine and proline in the B chain, used in the treatment of type 1 and type 2 diabetes.

insulin lispro

a pancreatic hormone.
indications It is used to treat ketoacidosis types I and II and types 1 and 2 diabetes mellitus.
contraindications Known hypersensitivity to this drug or to protamine prohibits its use.
adverse effects Anaphylaxis is a life-threatening effect of this drug. Other adverse effects include blurred vision, dry mouth, flushing, rash, urticaria, warmth, lipohypertrophy, swelling, redness, and rebound hyperglycemia (the Somogyi effect). Lipodystrophy and hypoglycemia are common side effects.

insulin lispro

A synthetic insulin with a very rapid onset and short duration of action. Diabetic patients typically use it immediately before meals to prevent postprandial hyperglycemia. Its absorption is more rapid than regular insulin. It is made by reversing the amino acids lysine and proline in the beta chain of the insulin polypeptide (hence its name lispro).
See also: insulin

insulin lispro

Very rapidly-acting INSULIN. A brand name is Humalog.
Mentioned in ?
References in periodicals archive ?
Admelog also was granted marketing authorization as a biosimilar, under the proprietary name Insulin lispro Sanofi, by the European Commission in July 2017, Sanofi added.
Sanofi achieves a first with Admelog
Hui et al6 studied the effects of insulin lispro Mix50 [50% short-acting lispro/50% intermediate-acting lispro protamine] and human insulin 30/70 on glycaemic control during Ramadan.
Risk stratification of persons on premixed insulin in Ramadan
This allowed insulin lispro injections to be passed through the abbreviated approval pathway under the Federal Food, Drug, and Cosmetic Act, formally known as the 505(b)(2) pathway.
FDA approves first follow-on short-acting insulin product using abbreviated approval
In one analysis, pegylated insulin lispro was associated with changes in HDL-C (0 to -5 mg/dL) and LDL-C (0 to 7 mg/dL) over 26 weeks.
Innovations in insulin for type 2 diabetes mellitus
The primary objective was to determine whether greater improvements in glycemic control could be achieved with insulin lispro premix 50/50 TID compared to insulin aspart premix 70/30 BID.
Better glycemic control with insulin premix 50/50 TID compared to insulin premix 70/30 BID/Premix 50/50 insulin ile premix 70/30 insuline kiyasla daha iyi glisemik kontrol mumkundur
15) reported on a sensitive RIA specific for insulin lispro.
Performance evaluation and cross-reactivity from insulin analogs with the architect insulin assay
The study, "Basal Insulin: Continuous Glucose Monitoring Reveals Less Overnight Hypoglycemia with Continuous Subcutaneous Insulin Infusion than with Glargine," was designed to compare glycemic control in patients using an insulin pump to those using injections of glargine for basal control (background insulin delivered around the clock) and insulin lispro at mealtimes.
PUMP THERAPY BETTER THAN INJECTIONS FOR GLUCOSE CONTROL
Admelog was granted marketing authorisation under the proprietary name, Insulin lispro Sanofi, by the European Commission in July 2017, concluded the company.
Sanofi awarded US FDA's tentative approval for Admelog (insulin lispro injection) 100 units/ml
s insulin lispro protamine suspension has been studied with favorable results as part of a basal-bolus approach in patients with type 1 diabetes (Diabet.
What's new in insulins and delivery systems: intranasal, buccal, oral, peritoneal, and even rectal insulins are in various stages of development
The trial compared two treatment strategies: (1) a postprandial strategy--premeal insulin lispro with basal insulin at bedtime if needed (neutral protamine Hagedorn [NPH] insulin), targeting 2-hour PPG [less than or equal to] 7.
Overview of insulin replacement therapy
Results from previous studies have shown that both insulin lispro and insulin aspart are safe and effective for CSII in adults with type 1 diabetes, and that CSII is as effective as multiple daily insulin injections.
Two insulin analogs work equally well in pumps

Medical browser ?
Full browser ?